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Introduction
Recently, the therapeutic options for the treatment of lupus
nephritis (LN) have increased by the promising results of
treatment with mycophenolate mofetil (MMF), anti-CD20
and other biological medications. However, whether these
treatments will reduce the ultimate development of end-
stage renal failure (ESRF) is not known yet. Although
compared to prednisone monotherapy, treatment with pred-
nisone and cyclophosphamide or azathioprine reduces the
cumulative incidence of ESRF in LN; still 20% of the pa-
tients develop ESRF [1]. In this editorial, we will review the
results of the various forms of renal replacement therapy
[i.e. haemodialysis, peritoneal dialysis and (pre-emptive)
renal transplantation] in patients with ESRF due to LN.
Haemodialysis
Initially, there was reluctance to dialyse lupus patients with
ESRF because of the systemic nature of the disease and the
(previous) use of immunosuppressives. In 1973, Coplon
and colleagues documented that haemodialysis and renal
transplantation in lupus patients had a favourable short-
term prognosis, which was confirmed in an extended report
after 12 years of experience [2].
Thereafter, numerous reports of single-centre experience
confirmed that in general, survival of lupus patients on
haemodialysis was comparable or even better than that in
non-lupus patients. In an extensive review of the literature,
Mojcik and Klippel [3] found that survival of lupus pa-
tients on dialysis of 80–90% at 5 years was comparable
to that in non-SLE dialysis patients and better than that in
other systemic autoimmune diseases. However, lupus pa-
tients on dialysis were younger and predominantly females,
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both factors which have a favourable impact on survival. In
general, clinical and serological disease activity decreased
during dialysis, notwithstanding the fact that the degree of
immunosuppression could be lessened. An analysis that we
performed in 55 lupus patients undergoing dialysis treat-
ment illustrates this [4]. In only 8% of patients, disease
activity increased, and in >50% disease activity decreased
or disappeared (P < 0.001). The percentage of patients us-
ing high dose of prednisone decreased from 69% to 15%
and the use of cytotoxic drugs from 72% to 7%. Although
disease activity in general tends to quench, there are some
reports on ongoing extrarenal disease activity in the first
year after the initiation of haemodialysis [5,6], especially
in black patients [7]. Patients who developed ESRF within
a short time period due to a rapidly progressive LN behave
differently. In 10–20% of these patients, renal function may
(partly) recover within a 4-month period [2], which allows
cessation of haemodialysis. These patients very often also
show persistence of considerable disease activity during
initial dialysis treatment, necessitating the continuation of
immunosuppressive treatment. Early mortality of lupus pa-
tients on haemodialysis is frequently the result of infection
rather than of active lupus [3].
A potential problem in lupus patients on haemodialysis
is the presence of anti-phospholipid antibodies (aPL) or
even of the anti-phospholipid syndrome (APS). There are
no prospective studies available on whether vascular ac-
cess thrombosis/stenosis occurs more frequently in lupus
patients on haemodialysis. Some reports suggest that SLE
patients have an increased risk [8,9]. This was recently con-
firmed in a retrospective case-control study in 36 lupus and
control patients on haemodialysis [10]. After 1 year, 66.6%
of the lupus patients had developed vascular access throm-
bosis compared to 38.9% in the control group [odds ratio:
3.1 (95% CI: 1.2–8.2)]. Unfortunately, the presence of aPL
was not assessed. Other symptoms of APS like myocardial
infarction or cerebral stroke were not more frequent in lu-
pus patients on dialysis; however, again the association with
aPL or APS was not evaluated [11].
Peritoneal dialysis
Data on CAPD treatment in lupus patients are more scarce.
Early experience suggested that lupus disease activity was
more prominent during CAPD than during HD, while data
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Table 1. Infectious complications and outcome in lupus patients with ESRF treated with CAPD
Huang et al. [14] Siu et al. [15]
SLE Controls SLE Controls
Males/females (n) 3/20 6/40 5/13 10/26
Age (years) 33.9 ± 7.6 34.3 ± 7.4 40.8 ± 10.3 42.2 ± 7.3
Duration of PD (months) 44.9 ± 24.0 47.3 ± 35.3 35.4 ± 20.7 36.7 ± 28.2
Albumin (g/dl) 31.6 ± 5.0∗ 35.2 ± 5.0 30.4 ± 6.6∗ 35.4 ± 5.6
Immunosuppression at start of PD (%) 56.5 ? 88.8 5.5
Peritonitisa 0.38+ 0.18 0.68§ 0.28
Exit-site infectiona 0.24∗ 0.12 0.24 0.20
Other infections ? ? 0.80∗ 0.13
Sepsis (n/total n) 5/23∗ 2/46 ? ?
Mortality (%) 35∗ 11 28# 6
Technique failure (%) 35∗ 9 11 6
aEpisodes/patient-year.
∗P < 0.01.
+P < 0.0001.
§P < 0.02.
#P < 0.05.
on survival were lacking [12].We conducted a retrospective
analysis on dialysis treatment in 55 patients with ESRF sec-
ondary to LN [4]. In this study, 23 patients on CAPD and
32 patients on HD were included with a median duration of
dialysis of 36 months. Survival at 5 years on CAPD and HD
was not significantly different (80%and 92%, respectively).
Data on disease activity, as measured with the Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI),
time-adjusted event rates and use of immunosuppressive
drugs, were not different between CAPD andHD treatment.
In both treatment groups, disease activity diminished simi-
larly. The number of patients with high non-renal SLEDAI
(> 10 points) decreased from 31% to 14%, the number of
complete remissions (non-renal SLEDAI 0) increased from
4% to 35% and intermittent disease activity (SLEDAI 1–
10) was present in 51% during dialysis. The event rates
for the different disease manifestations were not different
between CAPD- and HD-treated patients, except for throm-
bocytopaenia and elevated anti-dsDNA antibodies, which
occurred significantly more frequently during CAPD. As
stated before, this decrease in disease activity occurred,
while immunosuppressive treatmentwas tapered off consid-
erably. A more recent retrospective chart review does show
a significant difference in disease activity between HD and
CAPD. The follow-up maximal SLEDAI score increased
during peritoneal dialysis, but the long-term prognosis
was not significantly different between these two treat-
ment modalities [13]. Two recent publications addressed
the incidence of peritonitis, other infections and outcome
in lupus patients on CAPD in comparison with matched
non-lupus controls [14,15]. The results are summarized in
Table 1. In both studies, controls were matched for age and
gender and recruited in the same period, and diabetes pa-
tients were excluded from the control group. In the study of
Siu et al. [15], the control patients had biopsy-proven non-
lupus glomerulonephritis. Risk factors for infectious com-
plications were a significant lower albumin level at start of
PD and the high proportion of patients still on immunosup-
pressives. In both studies, significant higher incidences of
peritonitis and other infections were observed in lupus pa-
tients. Exit site infections were higher in the study of Huang
et al. [14]. Also, overall mortality was higher in the SLE
group (32%) than in the control group (9%). Finally, in one
study [14], one-third of the lupus patients had to discon-
tinue CAPD. The impact of immunosuppression on the high
incidence of peritonitis and other infections in CAPD pa-
tients is further documented by a study fromGuy’s Hospital
[16]. They analysed peritonitis incidence in a cohort of pa-
tients treated with CAPDwithin a 1-year time period, using
(n = 39) or not using (n = 146) immunosuppressives. Im-
munosuppressives were prescribed for various conditions;
the most prevalent reasons were glomerulonephritis, SLE
and vasculitis. The peritonitis frequency in the immuno-
suppressed patients was 1.8 episodes/patient-year and in
those without immunosuppression 0.68 (P < 0.001). This
was associated with a higher hospital admission rate (64%
versus 22%; P < 0.001) and a greater necessity of PD-
catheter removal (28.2% versus 9.6%; P< 0.01). Although
statistically not significant, there was a trend that sever-
ity of immunosuppression was associated with the num-
ber of CAPD peritonitis episodes. This study reveals that
immunosuppression is an important risk factor for CAPD
peritonitis, irrespective of the disease for which immuno-
suppression is given. Apart from the short-term effects,
CAPD peritonitis may have additional serious side effects
in lupus patients. It can induce exacerbations of the disease
and it may contribute, especially in lupus patients, to the
development of encapsulating peritoneal sclerosis [17]. So
these data suggest that CAPDmay not be the first choice of
renal replacement therapy in lupus patients, who are still on
immunosuppressive therapy. However, one should realize
that also on haemodialysis infection is a leading cause of
mortality [3]. Prospective data are clearly needed compar-
ing infection rates in lupus patients on PD or HD.
Renal transplantation
Pre-transplant screening
Since lupus patients have an increased incidence of cardio-
vascular disease and mortality [18], they must be screened
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for the presence of coronary artery disease with either
dipyridamol thallium scintigraphy or dobutamin stress
echocardiography. If abnormal, a coronary angiography
should be performed and if necessary a coronary revas-
cularization. In addition, a careful clinical and serological
assessment needs to be done to determine lupus disease
activity. If the disease is active, the transplantation should
be postponed until disease quiescence is obtained. Espe-
cially patients who develop ESRFwithin a short time period
(<12 months) are at high risk for post-transplant com-
plications. The presence of aPL or the APS should be
evaluated, as the risk for the development of thrombotic
micro-angiopathy in the renal allograft and for trans-
plant vessel thrombosis is increased. Stone et al. fol-
lowed a group of 85 transplanted SLE patients. Fifteen
of the 25 patients with aPL suffered from a clinical
event associated with APS, while only 5 of the pa-
tients without aPL had such an event (P < 0.0001) [19].
Whether aPL positive patients should be treated peri-
and postoperatively with anti-coagulants is not known
yet. Moreover, anticoagulation perioperatively can lead to
serious bleeding complications. In our unit, we treat all
renal transplant recipients with prophylactic doses of low-
molecular-weight heparin during the first week after trans-
plantation. Lupus patients have a high prevalence (30–90%)
of anti-lymphocyte antibodies [20]. Thismay cause positive
cross-matches. Therefore, during the pre-transplant work-
up cross-matches should be performed with autologous
lymphocytes. These results can be taken into account when
cross-matchingwith donor lymphocytes is performed.Most
lupus patients are extensively treated with corticosteroids
for their disease. Therefore, bone mineral density should
be assessed before transplantation to guide post-transplant
prophylaxis for osteoporosis with additional calcium, vita-
min D and eventually bisfosfonates. Obviously, also stan-
dard assessments should be carried out according to the
US or EDTA guidelines for pre-transplant screening. As in
every transplant candidate, the possibility of a pre-emptive
transplantation should thoroughly be investigated, because
of its superior results, which will be detailed below.
Cadaveric renal transplantation
The report of Coplon et al. in 1983 [2] indicated that the
results of renal transplantation in lupus patients were com-
parable to results in other patient groups. An analysis per-
formed by Nossent et al. on behalf of the Dutch Working
Party on SLE showed that patient survival after renal trans-
plantation at 1 year and another for 5 years was 86.5%
and graft survival was 67.6% and 54.1%, respectively [21].
However, in this study no comparisonwasmadewith results
in other patient groups. These data were confirmed by the
analysis of Mojcik and Klippel of 24 studies reported until
then in the literature [3]. They calculated an overall patient
survival of 86% and a graft survival after cadaveric renal
transplantation of 56%. Data from the Eurotransplant Reg-
istry [1] for first cadaveric renal transplants in the period
1984–1992 in 165 lupus patients compared to 21 726 non-
lupus patients showed similar graft survival at 1 year (80%
versus 82%) and 3 years (66% and 70%). Also, patient sur-
vival was similar at 1 year (95% versus 93%) and at 3 years
(92% versus 90%). However, the analysed studies differed
considerably with regard to number of patients, duration
of follow-up, ethnic composition, type of immunosuppres-
sion and period of transplantation. The single-centre study
of Stone et al. [22] corrected for these confounding factors
by using a control group of patients that was transplanted
in the same period, treated with either cyclosporine A or
tacrolimus and matched for age, sex, race, type of allograft,
number of previous transplants and year of transplantation.
In this analysis the outcome for lupus patients was less
favourable. The allograft survival for lupus patients ver-
sus controls was at 1 year: 81.7% versus 88.2%; at 2 years
74.7% versus 84.4%; at 5 years 45.9% versus 75% and at 10
years 18.5% versus 34.8%. The relative hazard ratio of allo-
graft loss in lupus patients was 2.1 (95%CI: 1.06–4.06;P<
0.04). The reasons for this increased allograft loss in lupus
patients was recurrence of LN leading to graft loss (3.8%)
and thrombosis or thrombotic microangiopathy attributed
to aPL (15.4%) [23]. These less favourable results were
not confirmed in an analysis using data from the United
States Renal Data System (USRDS). Ward [11] reported
that the hazard ratio adjusted for confounding factors for
graft loss in 772 lupus patients undergoing first cadaveric
renal transplantation was 1.08 (95% CI: 0.94–1.23; P =
0.28) compared to 32 644 control patients. Also, mortal-
ity did not differ between the groups. An analysis of the
United Network of Organ Sharing (UNOS) database [24]
also did not show a difference in patient and graft survival
between SLE patients and non-lupus patients after trans-
plantation with kidneys from either living (SLE: 789; non-
lupus: 21 228) or cadaveric donors (SLE 1170; non-lupus:
42 651). However, a recent large follow-up study using data
from both the USRDS and UNOS registry compared 2886
SLE recipients with 89 958 non-SLE recipients [25]. Lu-
pus patients showed a worse transplant (HR 1.09, 95% CI:
1.02–1.15, P < 0.05) and patient survival (HR 1.18, P <
0.05) compared to diabetes patients if corrected for many
confounding factors. There were no significant differences
when kidneys from living donors were transplanted.
These aggregated data, mainly from the USRDS [11]
and UNOS [24], indicate that graft survival and patient
survival in lupus patients are more or less comparable to
other patient groups although this is not confirmed in all
reports [25]. Less discrepancy is seen with regard to the
results of transplantation with kidneys from living donors
showing no differences between SLE and control patients
[24,25].
Living donor transplantation
Initial single centre reports indicated, as for transplantation
in other diseases, that results in lupus patients for living
donor transplantation (LDTx) were superior to cadaveric
donor transplantation (CADTx). Experience at the Univer-
sity of Wisconsin showed 5-year graft survival of LDTx
of 89% versus 41% in CADTx (P = 0.003) [26]. These
favourable results were confirmed in the USRDS analysis
[11]. In 390 lupus patients undergoing LDTx, 5-year graft
and patient survival were 77 and 94.4%, respectively, com-
pared to 58.1% and 83.3% in 772 lupus patients receiving
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Table 2. Cardiovascular risk factors of immunosuppressive drugs
Drug Hypertension Hyperlipidaemia Hyperglycaemia
Tacrolimus + ± +++
Cyclosporine ++ + +
Mycophenolic acid − − −
Azathioprine − − −
mTOR antagonists − +++ −/±
Prednisone +/++ ± ++
CADTx. Similar results were obtained in additional anal-
yses [24,25]. Therefore, LDTx is the preferred treatment
for SLE patients with ESRF. If a living donor is available,
the possibility of a pre-emptive transplantation should be
considered, since the results of such an approach are su-
perior in terms of graft and patient survival, irrespective
of the cause of the original kidney disease [27]. This will
prevent dialysis-associated morbidity, mortality, costs and
loss of quality of life. Pre-emptive transplantation should
not be pursued in those patients with ongoing disease activ-
ity or severe iatrogenic morbidity. A waiting period before
transplantation to obtain decreased disease activity and to
improve clinical condition might then be a better solution
[28].
Immunosuppressive therapy after renal transplantation
There are no prospective studies in lupus patients compar-
ing the effects of the various immunosuppressive drugs.
In general, it can be stated that the results of using cal-
cineurin blockers are superior. This is also observed in lupus
patients because 1-year graft survival in the cyclosporine
era was 89% compared to 68% in the pre-cyclosporine era
[26]. Therefore, immunosuppressive treatment in the induc-
tion phase of ∼6–12 months, aimed at prevention of acute
rejection episodes, should comprise calcineurin blockers.
However, the goals during the maintenance phase are dif-
ferent and aim at preservation of renal function, avoidance
of nephrotoxicity, reduction of risk factors for atheroscle-
rosis and suppression of lupus disease activity. Since lu-
pus patients have accelerated atherosclerosis [18], special
attention should be given to the impact of immunosup-
pressives on cardiovascular risk factors. These are semi-
quantitatively listed in Table 2. From this table it becomes
clear that during maintenance immunosuppression other
drugs (i.e. MMF or azathioprine) should be used prefer-
entially. Especially MMF is a good candidate because it
could have anti-atherogenic properties [29] and shows a
lower risk of graft loss (5-year graft loss 29.6% for lupus
recipients of a cadaveric donor graft who were on MMF
versus 40.2% for patients not on MMF) [24]. Recent stud-
ies have also indicated that MMF could have good efficacy
in treating LN although long-term studies are needed to
draw definite conclusions. If MMF usage leads to side ef-
fects, azathioprine forms a reasonable alternative. A draw-
back of both drugs is that they have to be combined with
low doses of prednisone with its inherent side effects, espe-
cially in lupus patients who already received corticosteroids
in their pre-transplant period. Therefore, Ponticelli has ad-
vocated a prednisone-free regimen by using cyclosporine
monotherapy [28]. The ultimate choice of the maintenance
immunosuppressive regimen in the individual lupus patient
after renal transplantation should be guided by the indi-
vidual characteristics of the patient, but the preference of
the authors is a combination of MMF and a low dose of
prednisone.
Recurrence of LN after renal transplantation
The general observation is that recurrence of LN in the re-
nal allograft is low with frequencies ranging from <1% to
3.8% [3]. However, some studies report a higher incidence
[30,31]. In some of these studies, rather aspecific findings
like mesangial proliferation were scored as recurrence. A
careful review of 106 transplant biopsies in 97 lupus pa-
tients revealed histological recurrence in nine cases (8.4%)
[32]. This recurrence contributed to graft loss in four of
the nine cases (3.8%). So even with a meticulous analy-
sis of transplant biopsies, the recurrence rate is rather low
compared to other glomerular diseases. Since it has been
reported that recurrent lupus nephritis responded well to
MMF, further studies are needed to see whether mainte-
nance treatment with MMF will decrease the recurrence
rate further.
Lupus disease activity after renal transplantation
In most studies, lupus disease activity declines further af-
ter renal transplantation. The overall incidence of extra-
renal flares after transplantation in a number of studies was
5.7% as calculated by Mojcik and Klippel [3]. The study
by Nossent et al. [21] revealed that the maximal non-renal
SLEDAI decreased after transplantation compared to dur-
ing dialysis and before dialysis. None of the patients after
transplantation had SLEDAI values >10%, and 71% had
SLEDAI values of 0. So it appears that either due to the
natural course of the disease and/or because of the contin-
uous use of immunosuppressives, lupus disease becomes
quiescent after renal transplantation.
Summary
Treatment of lupus patients with haemodialysis has com-
parable results as in non-lupus patients. In contrast, during
CAPD treatment peritonitis, other infectious complications
and technique failure are more frequent in lupus patients,
with an increased overall mortality. Therefore, haemodial-
ysis is preferred over CAPD, especially if the patient is still
using immunosuppressives. During both dialysismodalities
in general, disease activity decreases, which enables taper-
ing off immunosuppression. During pre-transplant screen-
ing, special attention should be given to cardiovascular dis-
ease manifestations, lupus disease activity, the presence of
anti-phospholipid antibodies and anti-lymphocyte antibod-
ies and bone mineral density. Lupus patients are good can-
didates for renal transplantation. If possible, lupus patients
should be transplanted pre-emptively with a kidney from a
living donor since this approach leads to the best results.We
prefer maintenance immunosuppression after 6–12 months
without calcineurin blockers because they bear a higher
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cardiovascular risk than for instance MMF. After renal
transplantation lupus disease activity further declines. The
rate of recurrence of lupus nephritis in the renal allograft is
low (<4%).
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